Osteoporosis and Cardiovascular Disease: Brittle Bones and Boned Arteries, Is There a Link?
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Endocrine
- Vol. 23 (1) , 01-10
- https://doi.org/10.1385/endo:23:1:01
Abstract
Both osteoporosis and cardiovascular disease (CVD) are major public health problems leading to increased morbidity and mortality. Although traditionally viewed as separate disease entities that increase in prevalence with aging, accumulating evidence indicates that there are similar pathophysiological mechanisms underlying both diseases. In addition to menopause and advanced age, other risk factors for CVD such as dyslipidemia, oxidative stress, inflammation, hyperhomocystinemia, hypertension, and diabetes have also been associated with increased risk of low bone mineral density (LBMD). Elevated LDL and low HDL cholesterol are associated with LBMD, altered lipid metabolism is associated with both bone remodeling and the atherosclerotic process, which might explain, in part, the co-existence of osteoporosis and atherosclerosis in patients with dyslipidemia. Similarly, inflammation plays a pivotal role in both atherosclerosis and osteoporosis. Elevated plasma homocysteine levels are associated with both CVD and osteoporosis. Nitric oxide (NO), in addition to its known atheroprotective effects, appears to also play a role in osteoblast function and bone turnover. Supporting this notion, in a small randomized controlled trial, nitroglycerine (an NO donor) was found to be as effective as estrogen in preventing bone loss in women with surgical menopause. Statins, agents that reduce atherogenesis, also stimulate bone formation. Furthermore, bisphosphonates, used in the treatment of osteoporosis, have been shown to inhibit atherogenesis. Intravenous bisphosphonate therapy significantly decreases serum LDL and increases HDL in postmenopausal women. The exciting possibilities of newer pharmacological agents that effectively treat both osteoporosis and CVD hold considerable promise. However, it is important to emphasize that the current evidence linking both of these diseases is far from conclusive. Therefore, additional research is necessary to further characterize the relationship between these two common illnesses.Keywords
This publication has 98 references indexed in Scilit:
- Pitavastatin Enhanced BMP-2 and Osteocalcin Expression by Inhibition of Rho-Associated Kinase in Human OsteoblastsBiochemical and Biophysical Research Communications, 2001
- Mevastatin, an HMG-CoA Reductase Inhibitor, Reduces Stroke Damage and Upregulates Endothelial Nitric Oxide Synthase in MiceStroke, 2001
- Parathyroid Hormone-induced Bone Resorption Does Not Occur in the Absence of OsteopontinPublished by Elsevier ,2001
- Atherogenic High-Fat Diet Reduces Bone Mineralization in MiceJournal of Bone and Mineral Research, 2001
- Nitroglycerin Therapy Is as Efficacious as Standard Estrogen Replacement Therapy (Premarin) in Prevention of Oophorectomy-Induced Bone Loss: A Human Pilot Clinical StudyJournal of Bone and Mineral Research, 2000
- Chronic Intravenous Aminobisphosphonate Therapy Increases High-Density Lipoprotein Cholesterol and Decreases Low-Density Lipoprotein CholesterolJournal of Bone and Mineral Research, 2000
- Nitric Oxide Response to Shear Stress by Human Bone Cell Cultures Is Endothelial Nitric Oxide Synthase DependentBiochemical and Biophysical Research Communications, 1998
- Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA proteinNature, 1997
- Estrogen Increases Endothelial Nitric Oxide by a Receptor Mediated SystemBiochemical and Biophysical Research Communications, 1995
- Bone mineral density measured by dual energy X-ray absorptiometry in patients with non-insulin-dependent diabetes mellitusBone, 1993